Table of Contents
ISRN Ophthalmology
Volume 2011, Article ID 916789, 4 pages
Research Article

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration

Department of Ophthalmology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita 879-5593, Japan

Received 11 October 2011; Accepted 15 November 2011

Academic Editors: B. Bui and U. U. Inan

Copyright © 2011 Kisaburo Yamada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [2 citations]

The following is the list of published articles that have cited the current article.

  • Murat Aslankurt, Lokman Aslan, Adnan Aksoy, Burak Erden, and Osman Cekic, “The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration,” European Journal of Ophthalmology, vol. 23, no. 4, pp. 553–557, 2013. View at Publisher ยท View at Google Scholar
  • Karen Jhi Wen Chia, Dinesh Visva Gunasekeran, and Augustinus Laude, “The Impact of Switching Anti-Vascular Endothelial Growth Factor Therapy in the Management of Exudative Age-Related Macular Degeneration,” Ophthalmic Surgery, Lasers and Imaging Retina, vol. 48, no. 10, pp. 859–869, 2017. View at Publisher ยท View at Google Scholar